Soymilk or progesterone for prevention of bone loss
Given concerns over the use of hormone replacement therapy (HRT), women are seeking natural alternatives to cope with the symptoms and effects of menopause. The bone sparing effects of soy protein and its isoflavones is well established in animal studies, while 5 previous human studies on soy and bone have yielded variable outcomes due in part to their short duration of study. Progesterone has been suggested as a bone–trophic hormone, but the effect of long–term, low dose transdermal progesterone is unknown.
The aim of the study was to compare for the first time the long–term effects of soymilk, with or without isoflavones with natural transdermal progesterone, or the combination, on bone mineral density in the lumbar spine and hip.
Postmenopausal, Caucasian women with established osteoporosis or at least 3 risk–factors for osteoporosis, were randomly assigned, double–blind to one of four treatment–groups: soymilk containing isoflavones (soy+, n = 23), transdermal progesterone (TPD+, n = 22), or the combination of soy+ and TDP+,(n = 22) or placebo (isoflavone–poor soymilk, soy÷ and progesterone–free–cream TDP÷, n = 22). All subjects received comparable intakes of calcium, minerals and vitamins. Bone mineral content (BMC) and density (BMD) were measured in lumbar spine and hip by using dual–energy X-ray absorptiometry (DEXA) at baseline and after 2 years.
The percentage change in lumbar spine BMD and BMC respectively, did not differ from zero in the soy+ group (+1.1%, +2.0%) and TDP+ group (÷1.1%, +0.4 %) but significant bone loss occurred in the control group (÷4.2%,÷4.3 %) and the combined treatment group (÷2.8%, ÷2.4 %). No significant changes occurred for femoral neck BMD or BMC.
Daily intake of two glasses of soymilk containing 76 mg isoflavones prevents lumbar spine bone loss in postmenopausal women. Transdermal progesterone had bone–sparing effects but when combined with soy milk a negative interaction between the two treatments occurs resulting in bone–loss to a greater extent than either treatment alone.
Key wordssoy isoflavones genistein daidzein equol transdermal progesterone bone density bone conservation postmenopausal women
Unable to display preview. Download preview PDF.
- 9.Rassi CM, Lieberherr M, Chaumaz G, Pointillart A, Cournot G (2001) Daidzein inhibits osteoclast differentiation and activity in vitro. Ann Nutr Metab 45:230 (Abstract)Google Scholar
- 10.Cho Y, Chung S, Cho K, et al. (2002) Black bean (Rhynchosia molubilis,Yak-Kong) exerts a prominent estrogenic effect on the proliferation of human MG- 63 osteoblastic cells. J Nutr 132:614SGoogle Scholar
- 11.Chen X, Anderson JJB (2002) Effects of isoflavones on osteoblast proliferation and differentiation. J Nutr 132(3):616S (Abstract)Google Scholar
- 16.Clifton-Bligh PB, Baber RJ, Fulcher GR, Nery ML, Moreton T (2001) The effect of isoflavones extracted from red clover (Rimostil) on lipid and bone metabolism. Menopause 8:S259–S265Google Scholar
- 17.Morabitu N, Crisafulla A, Vergara C, GaudioA, Lasco MA, Frisina N, D’Anna R, Corrado F, Pizzoleo MA, Cincotta M Altavilla D, Ientile R, Squadrito F (2002) Effects of genistein and hormone-replacement therapy on bone loss in early postmenopausal women: A randomized double-blind placebo-controlled study. J Bone Miner Res 17(10):1904–1912PubMedGoogle Scholar
- 19.Mei J, Yeung SS, Kung AW (2001) High dietary phytoestrogen intake is associated with higher bone mineral density in postmenopausal but not premenopausal women. J Clin Endocrinol Metab 86(11):5217–5221Google Scholar
- 20.Gallagher JC, Rafferty K, Haynatzka V, Wilson M (2000) The effect of soy protein on bone metabolism. J Nutr 130:667S (abstr)Google Scholar
- 21.Vitolins M, Anthony M, Lenschik L, Bland DR, Burke GL (2002) Does Soy Protein and Its Isoflavones Prevent Bone Loss in Peri- and Postmenopausal Women? Results of a Two-Year Randomized Clinical Trial. J Nutr 132:582SGoogle Scholar
- 22.Prior JC, Vigna YM, Schechter MT, Burgess AE (1990) Spinal bone loss and ovulatory disturbances. N Engl J Med 323(18):S1221–S1227Google Scholar
- 23.Prior JC (1990) Progesterone as a Bone- Trophic Hormone. Endocrine Rev 11(2):S386–S398Google Scholar
- 24.Prior JC, Vigna YM, Alojado N (1991) Progesterone and the prevention of osteoporosis. Can J Ob/Gyn & Women’s Health Care 3(4):S178–S184Google Scholar
- 28.Nordisk Ministerråd (1996) Nordiska näringsrekommendationer. Nord 28, CopenhagenGoogle Scholar
- 31.Arjmandi BH, Birnbaum R, Goyal NV, et al. (1998) Bonesparing effect of soy protein in ovarian hormone-deficient rats is related to its isoflavone content. Am J Clin Nutr 68:364S–368SGoogle Scholar
- 35.Viereck V, Grundker C, Blaschke S, Siggelkow H, Emons G, Hofbauer LC (2002) Phytoestrogen genistein stimulates the production of osteoprotegerin by human trabecular osteoblasts. J Cell Biol 84(4):725–735Google Scholar
- 42.Tylavsky FA,Anderson JJ (1988) Dietary factors in bone health of elderly lactoovovegetarian and omnivorous women. Am J Clin Nutr 48(3S):842–849Google Scholar
- 45.Spence LA, Lipscomb ER, Cadogan J, Martin BR, Peacock M, Weaver CM (2002) Effect of soy isoflavones on calcium metabolism in postmenopausal women. J Nutr 132:581S (abstr)Google Scholar